Related Experiment Video

Updated: Nov 17, 2025

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.3K

Treatment for Oral Mucositis-Current Options and an Update of Small Molecules Under Development

Stephen T Sonis1

  • 1Division of Oral Medicine, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston; Primary Endpoint Solutions, Waltham, MA, USA. ssonis@pesclinical.com.

Current Treatment Options in Oncology
|February 17, 2021
PubMed
Abstract

Insights

Oral mucositis (OM), a severe side effect of cancer treatment, still lacks effective therapies. New treatments targeting early stages show promise for OM and similar conditions.

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Oral mucositis (OM) is a significant toxicity of cytotoxic cancer therapy impacting numerous patients.
  • Despite its prevalence, OM remains a critical unmet clinical need.
  • Understanding OM's complex pathogenesis offers targets for therapeutic development.

Purpose of the Study:

  • To evaluate novel therapeutic agents for oral mucositis.
  • To assess the efficacy of interventions targeting the early stages of the OM cascade.
  • To explore potential applications for related conditions sharing OM's pathobiology.

Main Methods:

  • Clinical trials were conducted to assess the efficacy of new therapeutic agents.
  • Interventions focused on interrupting the early biological cascade of mucositis.
  • Patient outcomes and toxicity profiles were evaluated.

Main Results:

  • Favorable results were observed in recent clinical trials.
  • Agents targeting early stages of the mucositis cascade demonstrated efficacy.
  • The findings suggest a positive outlook for OM treatment.

Conclusions:

  • Novel therapeutic strategies targeting early pathogenic events are promising for OM.
  • These approaches may also benefit other conditions with similar pathobiology.
  • Further research and development are warranted for effective OM management.
Keywords:
ChemotherapyClinical trialsHead and neck cancerMucositisRadiotherapy

More Related Videos

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction07:44

Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction

Published on: April 24, 2016

11.7K
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.2K

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
802
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
232
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
966
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
305
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
299